RxDoctor Payments Data

Sreedhar Devathi, MD

Nephrology · Duluth, MNNPI 1528208642

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (57.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Vantive US Healthcare LLC accounts for 77.3% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $877, more than ten times the $12 reported in 2021.

$1,134in general payments, 2019–2025

Across 13 payments — averaging $87.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vantive US Healthcare LLC$877
  • Travere Therapeutics, Inc.$129
  • Amgen$29
  • Nxstage Medical, Inc.$28
  • Akebia Therapeutics Inc$25
  • Fresenius USA Marketing, Inc.$24
  • plus $23 from 1 others

What the payments were for

  • Travel & lodging$65257%
  • Food & beverage$43438%
  • Education$484%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,134 in reported general payments places this provider in the 80th percentile of 208 nephrology providers in Minnesota.

See all nephrology providers in Minnesota

Medicare billing

Part B allowed, 2024
$139,666
Medicare patients
262
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$99,297
FarxigaDapagliflozin Propanediol44$46,785
LokelmaSodium Zirconium Cyclosilicate33$37,197
VelphoroSucroferric Oxyhydroxide14$36,355
Sevelamer Carbonate71$15,282
VeltassaPatiromer Calcium Sorbitex12$12,737
Calcitriol229$2,989
Hydralazine Hcl115$1,951
Torsemide40$1,691
Losartan Potassium129$1,290
Allopurinol52$919
Bumetanide12$783
Potassium Chloride29$766
Furosemide99$713
Calcium Acetate11$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$24$36,35514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 208 nephrology providers in Minnesota.

Other nephrology in Duluth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →